阿德福韦酯联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化临床观察

Clinical Efficacy of Adefovir Dipivoxil Combined with Compound Biejia Ruangan Troche in Treatment of Liver Fibrosis in Chronic Hepatitis B

目的:观察阿德福韦酯联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化的临床效果。方法:慢性乙型肝炎肝纤维化患者67例随机分为治疗组(34例)和对照组(33例)。治疗组采用阿德福韦酯联合复方鳖甲软肝片治疗,对照组采用单独阿德福韦酯治疗,两组疗程均为12个月。观察两组患者治疗前后的临床症状、肝功能、肝纤维化四项指标等变化。结果:治疗组患者治疗后上腹部疼痛、乏力、纳差改善率显著优于对照组(P<0.05);治疗组血清ALT的复常率明显高于对照组(P<0.05),但两组血清AST、TBIL比较差异无统计学意义(P>0.05);治疗组肝纤维化4项指标较对照组改善更显著(P<0.05)。结论:阿德福韦酯联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化能明显缓解临床症状,改善肝纤维化程度,提高临床疗效。

Objective:To observe the clinical efficacy of adefovir dipivoxil combined with compoundBiejia Ruangan troche in treatment of liver fibrosis in chronic hepatitis B.Methods:67cases of liver fibrosis patients were randomly divided into the treatment group(34cases)and the control group(33cases).The control group received adefovir dipivoxil treatment alone,while the treatment group received adefovir dipivoxil combined with compound Biejia Ruangan troche.The course of treatment was 12months.Then clinical manifestations were observed and liver function and 4liver fibrosis indexes before and after treatment were compared.Results:The symptoms of epigastric pain,fatigue and anorexia were improved in the treatment group(P<0.05),The normalization rate of ALT of the treatment group was superior to the control group(P<0.05),but there was no statistical difference in the AST and TBIL between two groups(P>0.05).The 4liver fibrosis indexes in the treatment group were lower than control group(P<0.05).Conclusion:Adefovir dipivoxil and compound Biejia Ruangan troche combination therapy on patients with liver fibrosis in chronic hepatitis B can significantly alleviate clinical symptoms,reduce degrees of liver fibrosis and improve clinical efficacy.